Takeda presents detailed results from TAK-881 trial at ESID

Takeda's ORZEYFUL (oveporexton) has launched in Japan and China for treating narcolepsy type 1, following approvals by local regulators. The drug, discovered by Takeda, is the first orexin receptor 2 agonist designed to address the underlying cause of the condition. It is expected to launch in the U.S. next month. Takeda plans to submit the drug for approval in other markets worldwide.

Takeda Pharmaceutical has launched ORZEYFUL, a new treatment for type 1 narcolepsy, in Japan and China. The drug, discovered by Takeda scientists, is designed to restore orexin signaling and address the biological cause of the disease. Clinical studies showed significant improvements in symptoms and quality of life compared to placebo. ORZEYFUL is an oral orexin receptor 2 (OX2R) agonist, and Takeda plans to launch it in the U.S. next month.

Takeda Pharmaceutical (TAK) presented Phase 2/3 study results for TAK-881, showing a 42.6% reduction in infusion time for Primary Immunodeficiency Disease (PID) patients. The therapy met primary endpoints, demonstrating comparable efficacy and safety to HYQVIA. Takeda plans regulatory submissions in 2026. TAK stock is currently trading at $18.66, up 0.76%.

Takeda (TSE:4502/NYSE:TAK) announced positive Phase 2/3 trial results for TAK-881, an investigational treatment for Primary Immunodeficiency Disease (PID). The study met its primary endpoint, showing pharmacokinetic comparability to HYQVIA. TAK-881 demonstrated reduced infusion times and volume while maintaining safety and efficacy. Takeda plans regulatory submissions in 2026. The trial included 43 participants aged 16 and older, with comparable infection rates and safety profiles to HYQVIA.

Takeda's zasocitinib showed superior efficacy over Bristol Myers Squibb's deucravacitinib in treating moderate to severe plaque psoriasis, with 36.5% of participants achieving complete clearance vs. 13.9%, according to a phase 3 study presented at the European Academy of Dermatology and Venerology Congress. Zasocitinib also demonstrated faster and more complete effects, with no new safety signals observed.

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.